Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit research and development (R&D) organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access.
Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative (DNDi) in May 2016, GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage R&D of new antimicrobial agents and diagnostics.
GARDP benefits from its unique parentage, drawing strength from both WHO’s mandate to drive the global response to antimicrobial resistance and set health priorities, and DNDi’s expertise in harnessing partnerships to build a pipeline for neglected diseases and deliver not-for-profit, needs-driven R&D.